Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is positioned for continued success with its diverse portfolio of products in the growing areas of neuroscience, cardiometabolic, cancer, and immunology. The company's strong performance and potential VC investments set them apart from competitors, with a focus on innovation and addressing global challenges. With their commitment to sustainability and strong financial stability, Eli Lilly is a strong choice for investors looking for long-term growth potential.

Bears say

Eli Lilly is a well-established pharmaceutical company with a diverse portfolio of products in several therapeutic areas. However, the increased competition in the pharmaceutical industry and potential threats from generics and biosimilars could impact Lilly's key products and overall revenue growth. Additionally, the company's reliance on a few key drugs for a significant portion of its revenue could leave it exposed to potential setbacks in research and development or regulatory challenges. Furthermore, despite its recent positive financial performance and raised guidance, the company's high valuation and potential for underperformance compared to its peers may make it a risky investment.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,223.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,223.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.